EDSA Stock Forecast: Edesa Biotech, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.01
−7.80% on the day

The median 12-month analyst price target for Edesa Biotech, Inc. is $19. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 49 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$29.5M
Ticker Nerd rank
49/ 100
Median analyst target
$19
Analysts covering
2
Revenue$0.0
Operating income−$5.4M
Net income−$5.4M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.6%
1M
−28.7%
YTD
+41.5%
1Y
+16.2%
From 52W high
−89.0%
From 52W low
+151.2%
$1
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Edesa Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
49/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
79
Momentum
67
Issuance
60
Volatility
54
Value
41
Revisions
39
Quality
31
Growth
14

Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (14): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EDSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EDSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26EDSAHigh $21Median $19Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$9
Low
$19
Median
$21
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Nov 2025HC Wainwright & Co.ReiteratesBuy$5.00
27 June 2025HC Wainwright & Co.AssumesBuy$5.00
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
20 Aug 2024HC Wainwright & Co.ReiteratesBuy$21
28 June 2024HC Wainwright & Co.ReiteratesBuy$21
14 Feb 2024HC Wainwright & Co.ReiteratesBuy$21
29 Nov 2023HC Wainwright & Co.MaintainsBuy$70 → $21
22 Nov 2023HC Wainwright & Co.ReiteratesBuy$10
12 Oct 2023Brookline CapitalMaintainsBuy$57
15 Aug 2023HC Wainwright & Co.MaintainsBuy$16 → $10
24 May 2023HC Wainwright & Co.ReiteratesBuy$16
15 Mar 2023HC Wainwright & Co.ReiteratesBuy$16
14 Feb 2023HC Wainwright & Co.ReiteratesBuy$16
20 Dec 2021HC Wainwright & Co.InitiatesBuy$16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EDSA.

Market Radar

This page is one stock. Monday covers all of them.

EDSA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

EDSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Edesa Biotech, Inc. returned +16.2% against +6.9% for the S&P 500, dividends included.

EDSA vs S&P 500, last 12 monthsTotal return, rebased to 100
02004006008001,000Jan 26Apr 26Jul 26Oct 26EDSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EDSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
52.9×

Cheaper than 1% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−122.9%

Higher than 11% of US stocks

Return on assets
−66.4%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Edesa Biotech, Inc. has a market value of $29.5M and an enterprise value of $19.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$14.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.9M.

  • Shares outstanding: 9.6M.

  • Edesa Biotech, Inc. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

EDSA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EDSAEdesa Biotech, Inc.$29.5M49
EXOZeXoZymes, Inc.$27.0M11
KLRSKalaris Therapeutics, Inc.$26.8M27
TELOTelomir Pharmaceuticals, Inc.$26.8M27
EYPTEyePoint, Inc.$26.6M21
LONALeonaBio, Inc.$26.4M25
PMNProMIS Neurosciences, Inc.$28.3M30

Take a look at EDSA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Edesa Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about EDSA

What is the EDSA stock price forecast for 2026-2027?

The median 12-month analyst price target for Edesa Biotech, Inc. is $19, with estimates ranging from $9 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EDSA stock a buy right now?

Of the 2 analysts covering Edesa Biotech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edesa Biotech, Inc. 49 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EDSA?

As at 21 Nov 2026, Edesa Biotech, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).

Will EDSA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $19, and Ticker Nerd's factor model ranks Edesa Biotech, Inc. 49 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EDSA stock forecast for 2030?

No analyst covering Edesa Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EDSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $21 over the next 12 months.

How has EDSA stock performed over the past year?

Edesa Biotech, Inc. returned +16.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Edesa Biotech, Inc. do?

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. Edesa Biotech’s current pipeline centers on host-directed and targeted therapies designed for medical dermatology and respiratory conditions, including investigational programs for acute respiratory distress syndrome, chronic allergic contact dermatitis, vitiligo, systemic sclerosis, and pulmonary fibrosis.

Company

About Edesa Biotech, Inc.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. Edesa Biotech’s current pipeline centers on host-directed and targeted therapies designed for medical dermatology and respiratory conditions, including investigational programs for acute respiratory distress syndrome, chronic allergic contact dermatitis, vitiligo, systemic sclerosis, and pulmonary fibrosis. The company’s work includes monoclonal antibody and topical treatment candidates intended to modulate immune pathways and address conditions with significant unmet medical needs. Edesa Biotech operates as a research and development organization, advancing its product candidates through clinical studies and related regulatory activities. Headquartered in Markham, Ontario, Canada, the company plays a specialized role in the biotechnology sector by focusing on diseases driven by dysregulated inflammatory and immune responses.

CEO Dr. Pardeep Nijhawan FRCPC, M.D. · 17 employees · Canada · https://www.edesabiotech.com